Censa is developing therapies for orphan metabolic diseases with earlier stage programs targeting central nervous system diseases
Biopterins are endogenous essential co-factors for aromatic amino acid hydroxylases enzymes
Defects in biopterin dependent biochemical pathways are associated with severe metabolic and neurologic pathologies
Developing Medicines to Improve the Lives of Patients with Debilitating Diseases
News & Media
Jan. 15, 2017 – Cambridge, Massachusetts. Censa Pharmaceuticals Inc. appointed Dan Levy, PhD as Vice President Manufacturing. Dan has served as a consultant for the past year and has been a significant contributor to Censa’s progress to date. His energetic and collaborative leadership provide cost-effective strategies supporting our various manufacturing projects.View Dan’s full bio.
Oct. 15, 2016 – Cambridge, Massachusetts – Censa Pharmaceutical Inc. appointed Neil Smith, PharmD, MBA as Vice President, Research & Development and as Head Operations. In this role, Dr. Smith brings extensive experience in research, clinical project management operations and regulatory processes for, and approvals of, pharmaceutical therapies. As a Senior Director of External Innovation […]
July 18, 2016 – Cambridge, Massachusetts – Censa Pharmaceutical Inc. completed a Series A round of financing from Arkin Bio Ventures and from senior biopharmaceutical executives. The current financing will allow Censa to aggressively accelerate product development towards regulatory approval in target orphan diseases.